

Biomarkers for Cancer Immunotherapy: The Importance of dMMR/MSI-H for Predicting Response in Solid Tumors

Sunday, 19 September 2021

18.45 – 20.15 CEST

Channel 3

Please join our expert faculty
for a 20-minute live Q&A:
19 September 2021 19.55 – 20.15 CEST

Faculty

Thierry André, MD (Chair)

Sorbonne University and
Saint-Antoine Hospital
Paris, France

Anna Tinker, MD, FRCPC

University of British Columbia
Vancouver, Canada

Josef Rüschoff, MD

Targos Molecular Pathology GmbH
Kassel, Germany

Symposium Agenda

Welcome and introduction

Prof Thierry André

Biomarkers for treatment with immune checkpoint inhibitors: Where are we now?

Prof Josef Rüschoff

Efficacy and safety profiles of immune checkpoint inhibitors in patients with dMMR/MSI-H advanced/recurrent endometrial cancer

Dr Anna Tinker

Efficacy and safety profiles of immune checkpoint inhibitors in patients with dMMR/MSI-H solid tumors

Prof Thierry André

Patient case report panel discussion: Biomarkers in pan-tumor treatment

Prof Thierry André

Dr Anna Tinker

Prof Josef Rüschoff